Clinical Trial

A Clinical Study of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCI

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 1, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
An Open-label, Sequential Dose Escalation/De-escalation Clinical Trial of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCI.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06533358
Lead Sponsor Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Conditions Acute Coronary Syndrome
Enrollment 20 participants
Start Date 2024-02-27
Primary Completion 2024-12 (estimated)
Study Completion 2025-07 (estimated)
Updated on ClinicalTrials.gov 2024-08-01